Healthcare Industry News: Transdermal
News Release - July 11, 2007
Dr. William E. Cochran Joins arGentis Board of DirectorsMEMPHIS, Tenn.--(HSMN NewsFeed)--arGentis Pharmaceuticals, LLC announces the appointment of Dr. William E. Cochran as an Executive Officer of the Company and that he will serve on its Board of Directors. Dr. Cochran served as President of the Southern College of Optometry (SCO) from 1984 to 2007. He is a 1968 graduate of SCO and during his term as President of the college, SCO became one of the premier optometry schools in North America with SCO graduates consistently performing in the top three schools on national board examinations. SCO's reserve fund increased from $2.8 million to $37 million while tuition has continuously decreased. Dr. Cochran's leadership resulted in many advances and milestones for SCO, notably the opening of a 55,000 square foot Eye Center in 2002. This Eye Center is the largest facility of its kind in the country, seeing more than 60,000 patients per year. In addition to his position at SCO, Dr. Cochran has served as the president of the Association of Schools and Colleges of Optometry; on the National Board of Examiners in Optometry; and as president of the Memphis Association of Colleges and Universities.
"We are very excited about having Dr. Cochran join our team," stated Tom Davis, arGentis' Chief Executive Officer. "His experience and leadership nationally in furthering education and research in the ocular sciences, as well as his in-depth knowledge of the arGentis dry eye therapies provides us an invaluable resource in moving our ocular products pipeline forward."
"I am extremely impressed with the management team at arGentis and feel honored to join in this exciting venture to bring a real solution to dry eye syndrome to market," said William Cochran. "Being involved from the beginning, leads me to believe the Southern College of Optometry and its research team there, have solved the problem."
arGentis licensed two Transdermal therapies for the treatment of dry eye syndrome (DES) from SCO in 2006 and is currently advancing this platform into clinical development. The Transdermal testosterone formulation treats DES in menopausal women, while the Transdermal progesterone formulation treats DES in the wider population, including younger women and men. Both therapies are uniquely applied in a cream formulation to the upper and lower eyelids, Transdermally delivering the active pharmaceutical ingredient directly to the affected glands.
About Dry Eye Syndrome
Dry eye syndrome (DES), also known as keratoconjuctivitas sicca (KCS), is one of the most common disorders of the eye. It is caused by a lack of tear quantity, or lack of tear quality, adequate tear production without the necessary elements to maintain them. DES affects as many as 20 million people in the U.S. and 100 million in the developed world.
arGentis Pharmaceuticals, LLC is a specialty pharmaceutical company located in Memphis, TN. The company seeks to in-license therapies for chronic diseases with demonstrated proof of concept for further development and commercialization.
Source: arGentis Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.